RVP

Retractable Technologies ($RVP) CEO Accumulates Shares 60+ Times Over Nine Months Despite $16M Annual Losses

03/28/2025 16:13

Retractable Technologies ($RVP) President Thomas Shaw has been consistently purchasing company shares over the past nine months. Most recently, on March 27, 2025, he acquired an additional 6,736 shares for approximately $4,969, continuing this pattern of steady accumulation. Retractable Technologies is a small medical device manufacturer that designs, develops, manufactures, and markets safety syringes and other safety medical products. The company's product line includes VanishPoint insulin syringes, tuberculin syringes, blood collection sets, and IV safety catheters, among others. What stands out is Shaw's consistent buying pattern. Since June of last year, this purchasing behavior has resulted in over 60 transactions, with several days of significant volume. On September 20, 2024, he purchased 71,422 shares (approximately $58,859) in a single transaction, and on February 18, 2025, he acquired 30,000 shares (approximately $23,547). Additional large purchases of 28,596 and 29,112 shares occurred in December and January, respectively. Even more notable is that these persistent purchases have occurred despite the company's challenging financial situation. According to the most recent financial data available, $RVP reported annual (TTM) revenue of $38.27 million with a net loss of $15.96 million and earnings per share (EPS) of -$0.53. In Q2 of last year, the company posted $6 million in sales with an operating loss of $5.8 million. According to footnotes on his stock transactions, Shaw has investment power over 500,000 shares as a trustee for the benefit of a family member and voting control over the remainder of the shares pursuant to a voting agreement. This indicates his substantial influence over the company's stock. From a price perspective, $RVP has shown considerable volatility. The stock fell to as low as $0.57 in mid-November 2024 but recovered to $0.85 by late January 2025. It is currently trading in the $0.70 range, with a 52-week range of $0.56 to $1.23. The company's market capitalization is approximately $21 million, firmly placing it in the micro-cap category. Medical device industry experts note that Retractable's safety syringe technology could play an important role in medical safety, but current financial difficulties may limit short-term growth. The company's beta of 2.09 indicates higher-than-market volatility. Insider buying, particularly from CEOs, is generally interpreted as a positive signal about a company's outlook. Shaw's steady purchases may indicate confidence in the long-term value despite current difficulties. However, investors should also consider the company's persistent losses and the high volatility risk typical of micro-cap stocks. $RVP's next earnings announcement is scheduled for May 14, 2025, which will be an important indicator of whether the company's financial situation is improving. Investors should watch for signs of performance improvement alongside whether Shaw's buying pattern continues.

You can receive notifications when news is published.